夏洪平

简介

夏洪平，男，医师/教授/博导，“江苏特聘教授”/“双创团队”领军人才/“双创人才”。2011年获香港大学博士学位，曾在维也纳医科大学癌症中心和新加坡国立癌症中心从事肿瘤分子病理和转化医学相关研究，已作为项目负责人（PI）主持新加坡国家医学研究委员会基金和保健服务集团基金及中国国自然基金多项，在Hepatology, Journal of Hepatology, ACS Nano和ACS Central Science等发表论著三十余篇，申请专利多项。目前担任国自然基金通讯评审，Clinical and Molecular Hepatology，Hepatoma Research和Glioma等杂志编委。

教育背景及工作经历

2017-至今   学院教授

2012-2017  新加坡国立癌症中心 Research Fellow

2007-2011  香港大学 化学生物学与肿瘤学 博士

2004-2007  中山大学 病理与病理生理学 硕士

1999-2004  皖南医学院 临床医学 本科

奖项及荣誉

1. 2018 Asia-Pacific Primary Liver Cancer Expert Meeting, Young Investigator AwardSeoul, South Korea.

2. 2018 河南省医学科学技术进步奖 壹等奖 （排名第二）。

3. 2017学院学科建设工作“先进个人”。

4. The Liver Week 2017/2018, Incheon, Korea. Best Presentation Award.

5. SingHealth Publish! Award (Outstanding) (2015/2016).

6. The 23rd Asia Pacific Cancer Conference, Bali, Indonesia (2015), Best Oral Presentation Award.

7. The 2012 International Society for Cell and Gene Therapy of Cancer Conference (ISCGT2012, Singapore), Beckman Poster Prize No.1.

8. Eurasia-Pacific Uninet Science and Technology Scholarships (the Republic of Austria, 2010).

学术兼职

美国癌症协会会员；新加坡国立癌症中心青年科学家协会委员会；世界中医药学会联合会肿瘤精准医学专业委员会；中国抗癌协会会员，肿瘤标准专业委员会，肿瘤病理专业委员会，肝癌专业委员会，肿瘤转移专业委员会，纳米肿瘤学专业委员会和肿瘤代谢专业委员会等。

承担科研课题

1. 江苏省特聘教授（2016特别优秀人才）项目，江苏省教育厅，2017.1-2019.12

2. 东南大学-学院合作研究项目(2017年重点项目)，2018.1-2020.12

3. 江苏省“双创团队”领军人才项目，2019-2021

4. 江苏省“双创人才”项目，2019-2021

近五年代表性论文、专利

1. Xia H, Chen J, Shi M, Gao H, Sekar K, Seshachalam VP, Ooi LL, Hui KM. EDIL3 is a novel regulator of epithelial mesenchymal transition controlling early recurrence of hepatocellular carcinoma. J Hepatol. 2015 Oct; 63(4):863-73.

2. Ling D*, Xia H*, et al. pH-Sensitive Nanoformulated Triptolide as a Targeted Therapeutic Strategy for Hepatocellular Carcinoma. ACS Nano. 2014 Aug 26;8(8):8027-39. (*Co-first author).

3.  Xia H, et al. MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013 Aug; 58(2):629-41.

4. Xia H, et al. pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and Heterogeneous Stemness of Hepatocellular Carcinoma.ACS Cent. Sci., 2016, 2 (11), pp 802–811.

5. Xia H, et al. MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence. Cancer Lett. 2016 Dec 1;383(1):85-93.

6. Chen J, Xia H, et al. ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma. J Hepatol. 2015 Jun;62(6):1287-95.

7. Chen J, MuthukumarRajasekaran, Xia H,….The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway. Gut. 2016 Sep;65(9):1522-34.

8. Han J*, Xia H*, Wu Y, Kong SN, Deivasigamani A, Xu R, Hui KM, Kang Y. Single-layer MoS2 nanosheet grafted upconversion nanoparticles for near-infrared fluorescence imaging-guided deep tissue cancer phototherapy. Nanoscale. 2016 Apr 14;8(15):7861-5. (*Co-first author).

9. Xia H, Hui KM. Emergence of aspirin as a promising chemopreventive and chemotherapeutic agent for liver cancer. Cell Death Dis. 2017 Oct 12;8(10):e3112.

10. Xia H, Lee KW, Chen J, Kong SN, Sekar K, Deivasigamani A, Seshachalam VP, Goh BKP, Ooi LL, Hui KM. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. Cell Death Discov. 2017 Sep 11;3:17058.

11. Chen J, Rajasekaran M, Xia H,… CDK1-mediated BCL9 phosphorylation inhibits clathrin to promote mitotic Wntsignalling. EMBO J. 2018 Oct 15;37(20). pii: e99395.

12. Yuan J, Ng WH, Lam PYP, Wang Y, Xia H, ….The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants.Oncogene. 2018 Jun 21.